MK-0429

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameMK-0429
Drug Alias NameMK-429MK-0429L-000845704
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsOsteoporosis, PostmenopausalProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsOsteoporosis, PostmenopausalProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A